Regulation of the effector function of CD8<sup>+</sup> T cells by gut microbiota-derived metabolite butyrate.

Luu M, Weigand K, Wedi F, Breidenbend C, Leister H, Pautz S, Adhikary T, Visekruna A. · 2018

Read Regulation of the effector function of CD8<sup>+</sup> T cells by gut microbiota-derived metabolite butyrate. by Luu M, Weigand K, Wedi F, Breidenbend C, Leister H, Pautz S, Adhikary T, Visekruna A. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6158259.txt.

Introduction

Luu and co-authors present a research article in Scientific Reports on how a gut microbe product steers killer T cells. Gut microbes make short-chain fatty acids that affect energy balance and immune cells. Giving these acids by mouth is being explored as a therapy for inflammatory disease. Most past work looked at CD4 T cells.

The team focused on CD8 cytotoxic T cells, which kill infected and abnormal cells. Butyrate, and propionate to a lesser degree, changed gene activity in these cells. Treated cells made more interferon gamma and granzyme B, tools for killing targets. Butyrate also switched Tc17 cells toward the killer type. The effect worked by blocking histone deacetylases, not the usual receptors.

Catalog record

CREATORLuu M, Weigand K, Wedi F, Breidenbend C, Leister H, Pautz S, Adhikary T, Visekruna A.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6158259

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Regulation of the effector function of CD8+ T cells by gut microbiota-derived metabolite butyrate By Maik Luu, Katharina Weigand, Fatana Wedi, Carina Breidenbend, Hanna Leister, Sabine Pautz, Till Adhikary, Alexander Visekruna Published in: Scientific Reports DOI: 10.1038/s41598-018-32860-x ABSTRACT Abstract The gut microbiota produces metabolites such as short-chain fatty acids (SCFAs) that regulate the energy homeostasis and impact on immune cell function of the host. Recently, innovative approaches based on the oral administration of SCFAs have been discussed for therapeutic modification of inflammatory immune responses in autoimmune diseases. So far, most studies have investigated the SCFA-mediated effects on CD4+ T cells and antigen presenting cells. Here we show that butyrate and, to a lesser degree, propionate directly modulate the gene expression of CD8+ cytotoxic T lymphocytes (CTLs) and Tc17 cells. Increased IFN-γ and granzyme B expression by CTLs as well as the molecular switch of Tc17 cells towards the CTL phenotype was mediated by butyrate independently of its interaction with specific SCFA-receptors GPR41 and GPR43. Our results indicate that butyrate strongly inhibited histone-deacetylases (HDACs) in CD8+ T cells thereby affecting the gene expression of effector molecules. Accordingly, the pan-HDAC inhibitors trichostatin A (TSA) and sodium valproate exerted similar influence on CD8+ T cells. Furthermore, higher acetate concentrations were also able to increase IFN-γ production in CD8+ T lymphocytes by modulating cellular metabolism and mTOR activity. These findings might have significant implications in adoptive immunotherapy of cancers and in anti-viral immunity. INTRODUCTION The short-chain fatty acids (SCFAs) acetate, propionate and butyrate are synthesized in the intestinal lumen of caecum and large intestine by bacterial fermentation of non-digestible, complex carbohydrates such as dietary fiber1. SCFAs are capable of crossing the intestinal epithelium and of reaching the lamina propria, where they can directly shape mucosal immune responses. A high intake of dietary fiber or oral administration of SCFAs have been shown to mediate protective effects in experimental models of colitis, multiple sclerosis, type 1 diabetes, allergic airway inflammation and food allergy2–6. Acetate, which is the most abundant SCFA in the intestinal lumen, has been shown to be an important substrate for hepatic lipogenesis. Propionate can also be metabolized in the liver acting as substrate for the hepatic gluconeogenesis. Butyrate, which is mainly produced by strictly anaerobic spore-forming bacteria such as Clostridium butyricum, is used locally as energy source for colonocytes7. Novel reports have found that butyrate and other SCFAs are able to interact with their specific receptor GPR43, which is selectively expressed on colonic regulatory T cells (Tregs)8. Alternatively, SCFAs taken up by mucosal T cells act directly in the nucleus as histone deacetylase (HDAC) inhibitors, thereby promoting differentiation of peripheral Tregs. This effect of butyrate on Tregs can be explained by increasing the acetylation of histones H3 and H4 at the Foxp3 gene locus9,10. Taken together, SCFAs that are absorbed first into colonocytes and then into mucosal immune cells profoundly impact on intestinal homeostasis by inducing generation of Tregs, by enhancing the gut barrier function and by influencing signaling pathways that govern dendritic cells (DCs) to a tolerogenic state7. While the anti-inflammatory capacity of butyrate and other SCFAs has been extensively investigated, novel studies have revealed that CD4+ effector T cells might also be a cellular target for SCFAs11–14. Therefore, it will be particularly interesting to better understand the molecular mechanisms underlying cell- and tissue-specific responsive immune cell subsets in order to develop and provide a safe SCFA-based therapy for patients with autoimmune diseases. Due to their HDAC-inhibitory activity and strong interaction with cell surface receptors such as GPR41, GPR43 and GPR109A, SCFAs have a strong potential to regulate the function of immune cells in extra-intestinal organs as well (particularly if administered intravenously or intraperitoneally). So far it has clearly been demonstrated that SCFAs are able to modulate the phenotype and function of numerous immunologically relevant cells such as colonic epithelial cells, macrophages, neutrophils and DCs15–18. The unanswered question is if microbial metabolites are capable of regulating the gene expression and function of CD8+ T lymphocytes. Our current findings suggests a strong effect of butyrate on two CD8+ T cell subsets, cytotoxic T lymphocytes (CTLs) and Tc17 cells. Several lines of evidence point to epigenetic regulatory mechanisms causing effects of butyrate on CD8+ T cell function. Thus, our study supports the concept that SCFAs not only optimize the function of Tregs and conventional CD4+ T cells, but also modulate the expression of effector molecules in CD8+ T lymphocytes in a context-specific manner. RESULTS Butyrate promotes the increased expression of IFN-γ and granzyme B in CTLs and Tc17 cells To investigate if SCFAs are able to influence the phenotype of CD8+ T cells, we treated CTLs and Tc17 cells with acetate, propionate and butyrate for three days and measured the expression of IL-17A and IFN-γ in both CD8+ T cell subsets by flow cytometry. As compared to acetate-treated or untreated T cells, the frequency of IFN-γ+ cells increased significantly following butyrate treatment of both, CTLs and Tc17 cells (Fig. 1a–f). Moreover, the reduction of IL-17A was detected in Tc17 cells treated with butyrate but not with acetate. Propionate treatment also led to increased percentages of IFN-γ+ cells, however this effect was less pronounced as compared to the treatment with butyrate. We next investigated whether in vivo treatment with butyrate could specifically alter IFN-γ production by CD8+ T cells. To test if IFN-γ production in CD8+ T cells might be upregulated by butyrate, WT mice were orally treated with this SCFA for three weeks (according to the published protocol8) and afterwards the frequency of IFN-γ-expressing CD8+ and CD4+ T cells in the spleen and mLNs was examined by FACS analysis. Intracellular staining revealed a slight, but reproducible increase in percentage of IFN-γ+ CD8+ T lymphocytes in mLNs but not in spleen (Fig. 1g,h). In contrast, CD4+ effector T cells derived from both organs were not able to increase their IFN-γ production after treatment with butyrate (Supplementary Fig. 1a,b). Negligible percentages of Th17 and Tc17 cells were measured in both tissues independently of butyrate treatment. Previously, it was demonstrated that early, autocrine IFN-γ signaling promotes the CTL cell differentiation and upregulates T-bet and granzyme B expression in CD8+ T cells19. It is tempting to speculate that butyrate could locally enhance already high production of IFN-γ in mLNs by supporting the autocrine IFN-γ signals. [Figure: Treatment of CD8+ T cells with butyrate results in preferential increase of IFN-γ production. (a,b) Frequency of IFN-γ+ cells cultured under sub-optimal CTL-inducing conditions and treated with SCFAs (1 mM). (c) Relative mRNA expression of Ifnγ in CTLs treated with 1 mM of various SCFAs. (d–f) Frequencies of IFN-γ+ and IL-17A+ Tc17 lymphocytes upon treatment with SCFAs (1 mM). (g,h) Frequency of IFN-γ+ CTLs in mLNs and spleen four weeks after oral treatment of WT mice with 150 mM sodium butyrate. Two experiments with five mice per group were performed. (b,c,e,f) Data are pooled from three independent experiments. Results are expressed as mean ± SEM. n. s. = not significant, *p < 0.05, **p < 0.01, ***p < 0.001.] To test whether CTLs are able to upregulate their granzyme B expression upon SCFA treatment, we treated CD8+ T lymphocytes with acetate, propionate and butyrate for three days, and measured the concurrent production

Read the complete text